AKT serine/threonine kinase 3
Ultimo aggiornamento 18 Ago 2020
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Ask Patient
- Versione audio
- Aggiungi alle fonti preferite su Google
L AKT3 gene provides instructions for making a protein that is most active in the nervous system. The AKT3 protein is a key regulator of a chemical signaling pathway called the PI3K-AKT-mTOR pathway. This signaling influences many critical cell functions, including the creation (synthesis) of new proteins, cell growth and division (proliferation), and the survival of cells. The PI3K-AKT-mTOR pathway is essential for the normal development of many parts of the body, including the brain. Studies suggest that the AKT3 protein plays a critical role in determining brain size.
Scelte video per GenesVideo library
Normal function
L AKT3 gene provides instructions for making a protein that is most active in the nervous system. The AKT3 protein is a key regulator of a chemical signaling pathway called the PI3K-AKT-mTOR pathway. This signaling influences many critical cell functions, including the creation (synthesis) of new proteins, cell growth and division (proliferation), and the survival of cells. The PI3K-AKT-mTOR pathway is essential for the normal development of many parts of the body, including the brain. Studies suggest that the AKT3 protein plays a critical role in determining brain size.
Conditions referring to this gene or chromosome
Altri nomi
PKB gamma
PKB-GAMMA
PKBG
PRKBG
RAC-gamma
RAC-gamma serine/threonine protein kinase
RAC-PK-gamma
STK-2
v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)
Related patient information and medicines

Patient information leaflet
Disordini di accumulo di glicogeno
Disordini di accumulo di glicogeno are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most are diagnosed in childhood. Symptoms include weakness,.

Patient information leaflet
Cancro primario al fegato
Cancro primario al fegato è uncommon in the UK but is common in other parts of the world. In the UK, most cases develop as a complication of scarring of the liver (cirrhosis). In general the outlook is poor. There are new medicines being developed for the treatment of liver cancer. For example, sorafenib is a type of medicine called a multi-targeted.

Patient information leaflet
Distrofia muscolare
Also, if a child has delayed motor milestones (as mentioned above), a doctor may advise testing for MD, even though the problem could be due to another cause. MD may be diagnosed using one or more of the following tests: A blood test Blood tests for creatine kinase (CK) - in many types of MD, the blood level of CK is very high. A muscle biopsy.

Patient information leaflet
Cancro alla bocca
Diagnosing mouth cancer Your healthcare professional may suspect mouth cancer if you have a lesion in your mouth (such as a sore, an ulcer or a lump) which has not healed for 3 wee... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or.

Patient information leaflet
Artrite idiopatica giovanile
As they are relatively new medicines, there are still studies being done to establish whether there are any long-term health risks from taking them. Options include: Etanercept Etanercept Tocilizumab Infliximab Abatacept Adalimumab Tofacitinib is another new drug. It belongs to a type of drug called JAK kinase inhibitors. It is sometimes used if.

Patient information leaflet
Pompholyx
Its effectiveness for pompholyx is still being stud... Dapilumab : this medication is used for a type of eczema called atopic dermatitis. In some cases it has been shown to be helpful for the treatment of pompholyx. Janus Kinase (JAK) inhibitors : these medications, available as creams or pills, target specific pathways involved in inflammation..
Ulteriori letture e riferimenti
- AKT serine/threonine kinase 3; MedlinePlus, National Library of Medicine.
- Ballif BC, Rosenfeld JA, Traylor R, Theisen A, Bader PI, Ladda RL, Sell SL, Steinraths M, Surti U, McGuire M, Williams S, Farrell SA, Filiano J, Schnur RE, Coffey LB, Tervo RC, Stroud T, Marble M, Netzloff M, Hanson K, Aylsworth AS, Bamforth JS, Babu D, Niyazov DM, Ravnan JB, Schultz RA, Lamb AN, Torchia BS, Bejjani BA, Shaffer LG. High-resolution array CGH defines critical regions and candidate genes for microcephaly, abnormalities of the corpus callosum, and seizure phenotypes in patients with microdeletions of 1q43q44. Hum Genet. 2012 Jan;131(1):145-56. doi: 10.1007/s00439-011-1073-y. Epub 2011 Jul 29.
- Cohen MM Jr. The AKT genes and their roles in various disorders. Am J Med Genet A. 2013 Dec;161A(12):2931-7. doi: 10.1002/ajmg.a.36101. Epub 2013 Sep 3.
- Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathern GW, Gleeson JG. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 2012 Jun 24;44(8):941-5. doi: 10.1038/ng.2329.
- Mirzaa G. MPPH Syndrome. 2016 Nov 17 [updated 2022 Jul 28]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK396098/
- Mirzaa GM, Riviere JB, Dobyns WB. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP. Am J Med Genet C Semin Med Genet. 2013 May;163C(2):122-30. doi: 10.1002/ajmg.c.31361. Epub 2013 Apr 16.
- Nakamura K, Kato M, Tohyama J, Shiohama T, Hayasaka K, Nishiyama K, Kodera H, Nakashima M, Tsurusaki Y, Miyake N, Matsumoto N, Saitsu H. AKT3 and PIK3R2 mutations in two patients with megalencephaly-related syndromes: MCAP and MPPH. Clin Genet. 2014 Apr;85(4):396-8. doi: 10.1111/cge.12188. Epub 2013 Jun 10. No abstract available.
- Nellist M, Schot R, Hoogeveen-Westerveld M, Neuteboom RF, van der Louw EJ, Lequin MH, Bindels-de Heus K, Sibbles BJ, de Coo R, Brooks A, Mancini GM. Germline activating AKT3 mutation associated with megalencephaly, polymicrogyria, epilepsy and hypoglycemia. Mol Genet Metab. 2015 Mar;114(3):467-73. doi: 10.1016/j.ymgme.2014.11.018. Epub 2014 Dec 5.
- Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BF, Riviello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 2012 Apr 12;74(1):41-8. doi: 10.1016/j.neuron.2012.03.010.
- Riviere JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggar AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL; Finding of Rare Disease Genes (FORGE) Canada Consortium; Majewski J, Bulman DE, O'Driscoll M, Shendure J, Graham JM Jr, Boycott KM, Dobyns WB. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012 Jun 24;44(8):934-40. doi: 10.1038/ng.2331.
- Wang D, Zeesman S, Tarnopolsky MA, Nowaczyk MJ. Duplication of AKT3 as a cause of macrocephaly in duplication 1q43q44. Am J Med Genet A. 2013 Aug;161A(8):2016-9. doi: 10.1002/ajmg.a.35999. Epub 2013 Jun 21.
Condividi i tuoi pensieri o esperienze con gli altri nel nostro comunità di pazienti.
Iscriviti alla newsletter di Patient
La tua dose settimanale di consigli sulla salute chiari e affidabili - scritti per aiutarti a sentirti informato, sicuro e in controllo.
Abbonandoti accetti i nostri Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.

